

Confirmed Speakers

Confirmed Speakers

QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases



Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis



Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States)

First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases



Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany)

Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other



Dr Uwe GRETHNER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations



Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)

Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH



Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan)

Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma



Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden)

Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy



Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany)

Confirmed Speakers

GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)



Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)